DE60238485D1 - Humanisierte antikörper gegen icam-1, deren herstellung und verwendungen - Google Patents
Humanisierte antikörper gegen icam-1, deren herstellung und verwendungenInfo
- Publication number
- DE60238485D1 DE60238485D1 DE60238485T DE60238485T DE60238485D1 DE 60238485 D1 DE60238485 D1 DE 60238485D1 DE 60238485 T DE60238485 T DE 60238485T DE 60238485 T DE60238485 T DE 60238485T DE 60238485 D1 DE60238485 D1 DE 60238485D1
- Authority
- DE
- Germany
- Prior art keywords
- icam
- humanized antibodies
- preparation
- antibodies
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 title abstract 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/910,483 US20030035798A1 (en) | 2000-08-16 | 2001-07-19 | Humanized antibodies |
PCT/US2002/023002 WO2003035696A2 (en) | 2001-07-19 | 2002-07-19 | Humanized antibodies against icam-1, their production and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60238485D1 true DE60238485D1 (de) | 2011-01-13 |
Family
ID=25428849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60238485T Expired - Lifetime DE60238485D1 (de) | 2001-07-19 | 2002-07-19 | Humanisierte antikörper gegen icam-1, deren herstellung und verwendungen |
Country Status (10)
Country | Link |
---|---|
US (4) | US20030035798A1 (de) |
EP (2) | EP1414861B1 (de) |
JP (3) | JP4516312B2 (de) |
AT (1) | ATE490276T1 (de) |
AU (3) | AU2002363027C1 (de) |
CA (2) | CA2454361C (de) |
DE (1) | DE60238485D1 (de) |
DK (1) | DK1414861T3 (de) |
ES (1) | ES2356896T3 (de) |
WO (1) | WO2003035696A2 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE293994T1 (de) * | 1997-12-01 | 2005-05-15 | Fang Fang | Multivalente rekombinante antikörper zur behandlung von hrv infektionen |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
EP1578917A4 (de) | 2001-07-19 | 2008-01-23 | Perlan Therapeutics Inc | Multimere proteine und verfahren zu deren herstellung und verwendung |
WO2005086568A2 (en) * | 2004-01-26 | 2005-09-22 | Morphosys Ag | Anti-icam-1 human antibodies and uses thereof |
AR050642A1 (es) * | 2004-09-10 | 2006-11-08 | Wyeth Corp | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina |
GB2430030B (en) * | 2005-09-07 | 2009-04-01 | Ethicon Inc | Diagnostic markers of wound infection III |
GB0525214D0 (en) | 2005-12-12 | 2006-01-18 | Bioinvent Int Ab | Biological materials and uses thereof |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
WO2010112193A1 (en) * | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
BRPI1011805A2 (pt) | 2009-06-18 | 2016-10-11 | Pfizer | anticorpos anti incisura-1 |
SG179196A1 (en) | 2009-09-16 | 2012-04-27 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
GB2482535A (en) * | 2010-08-05 | 2012-02-08 | Hera Pharmaceuticals Inc | Expression of antibody or a fragment thereof in lactobacillus |
GB2482536B (en) | 2010-08-05 | 2013-07-24 | Hera Pharmaceuticals Inc | Expression of antibody or a fragment thereof in lactobacillus |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ジスルフィドによって安定化されたFv断片を含む二重特異性抗体 |
MX346995B (es) | 2010-12-15 | 2017-04-06 | Wyeth Llc | Anticuerpos anti-notch1. |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
CN103502271B (zh) | 2011-02-28 | 2016-10-26 | 霍夫曼-拉罗奇有限公司 | 抗原结合蛋白 |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
BR112014032193A2 (pt) | 2012-06-27 | 2017-06-27 | Hoffmann La Roche | métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico |
JP6422956B2 (ja) | 2013-10-11 | 2018-11-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性ドメイン交換共通可変軽鎖抗体 |
TW201623333A (zh) * | 2014-05-13 | 2016-07-01 | Chugai Pharmaceutical Co Ltd | 對具有免疫抑制機能之細胞的t細胞重定向抗原結合分子 |
JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性抗体 |
JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
FR2562421B1 (fr) | 1984-04-09 | 1989-02-17 | Sandoz Sa | Perfectionnements a la therapie par l'interleukine |
EP0169146A3 (de) | 1984-07-20 | 1988-07-20 | Merck & Co. Inc. | Monoklonale Antikörper gegen den Rezeptor des menschlichen Rhinovirus |
US4698420A (en) * | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
US5077195A (en) * | 1985-03-01 | 1991-12-31 | Board Of Reagents, The University Of Texas System | Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known and methods of design therefor |
US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
DE3682257D1 (de) | 1985-11-22 | 1991-12-05 | Takeda Chemical Industries Ltd | Liposomzusammensetzung. |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US6121424A (en) * | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
JP2666345B2 (ja) | 1987-04-16 | 1997-10-22 | 武田薬品工業株式会社 | リポソーム製剤およびその製造法 |
US5565550A (en) * | 1987-05-04 | 1996-10-15 | Dana Farber Cancer Institute | Antibodies to ICAM-2, and fragments thereof |
US5284931A (en) * | 1987-05-04 | 1994-02-08 | Dana Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
ES2080044T3 (es) | 1987-05-04 | 1996-02-01 | Dana Farber Cancer Inst Inc | Moleculas de adhesion intercelular y sus ligandos de fijacion. |
US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP0364096B1 (de) | 1988-09-06 | 2000-03-08 | Xoma Corporation | Genexpressions-Elemente und Herstellung von chimären Maus-Mensch-Antikörpern |
DE68923675T2 (de) | 1988-09-28 | 1996-02-15 | Dana Farber Cancer Inst Inc | Interzellulare Adhäsions-Moleküle und deren Bindungsliganden. |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JPH04503306A (ja) | 1989-02-01 | 1992-06-18 | ザ・ジェネラル・ホスピタル・コーポレーション | 単純ヘルペスウイルス1型発現ベクター |
US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
ES2035668T3 (es) | 1989-03-09 | 1993-04-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma. |
US5081584A (en) * | 1989-03-13 | 1992-01-14 | United States Of America | Computer-assisted design of anti-peptides based on the amino acid sequence of a target peptide |
AU627591B2 (en) | 1989-06-19 | 1992-08-27 | Xoma Corporation | Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen |
US5324510A (en) * | 1989-09-01 | 1994-06-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma |
WO1991007493A1 (en) | 1989-11-13 | 1991-05-30 | Xoma Corporation | Chimeric mouse human antibodies with specificity to hiv antigens |
EP0453561A4 (en) | 1989-11-13 | 1993-02-10 | Xoma Corporation | Chimeric mouse human antibodies with specificity to hiv antigens |
WO1991007418A1 (en) | 1989-11-13 | 1991-05-30 | Xoma Corporation | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
GB9009548D0 (en) | 1990-04-27 | 1990-06-20 | Celltech Ltd | Chimeric antibody and method |
GB9009549D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Recombinant antibody and method |
EP0459577A3 (en) | 1990-06-01 | 1992-08-05 | Merck & Co. Inc. | Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors |
US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
JPH06500923A (ja) | 1990-09-21 | 1994-01-27 | カイロン コーポレイション | パッケージング細胞 |
US5582996A (en) * | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
EP0572401B2 (de) | 1991-02-19 | 2007-11-07 | The Regents of the University of California | Viruspartikel mit veraendertem wirtspektrum |
GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
US5223396A (en) * | 1991-05-03 | 1993-06-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for detecting organ transplant rejection |
DK0590058T3 (da) * | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
EP0605522B1 (de) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methoden zur Herstellung humanisierter Antikörper |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
US5932448A (en) * | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
AU676150B2 (en) * | 1992-01-23 | 1997-03-06 | Merck Patent Gmbh | Monomeric and dimeric antibody-fragment fusion proteins |
US6129914A (en) * | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
WO1993019660A1 (en) | 1992-04-03 | 1993-10-14 | Baylor College Of Medicine | Gene therapy using the intestine |
US6329507B1 (en) * | 1992-08-21 | 2001-12-11 | The Dow Chemical Company | Dimer and multimer forms of single chain polypeptides |
US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5832448A (en) * | 1996-10-16 | 1998-11-03 | Health Hero Network | Multiple patient monitoring system for proactive health management |
WO1994012520A1 (en) * | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
DK0672142T3 (da) * | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
US6307026B1 (en) * | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
FR2702160B1 (fr) | 1993-03-02 | 1995-06-02 | Biovecteurs As | Vecteurs particulaires synthétiques et procédé de préparation. |
US5491074A (en) * | 1993-04-01 | 1996-02-13 | Affymax Technologies Nv | Association peptides |
WO1994026875A1 (en) * | 1993-05-18 | 1994-11-24 | I.D.M. Immuno-Designed Molecules | New macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions |
EP0728202A4 (de) | 1993-11-12 | 1997-04-23 | Univ Case Western Reserve | Episomales expressionsvektor für die menschliche gentherapy |
US5928944A (en) | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
US5731172A (en) | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
GB9409768D0 (en) * | 1994-05-16 | 1994-07-06 | Medical Res Council | Trimerising polypeptides |
US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
US5763733A (en) * | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
US5721340A (en) * | 1994-11-28 | 1998-02-24 | The Wistar Institute Of Anatomy & Biology | p53 proteins with altered tetramerization domains |
US5573925A (en) * | 1994-11-28 | 1996-11-12 | The Wistar Institute Of Anatomy And Biology | P53 proteins with altered tetramerization domains |
US5632448A (en) * | 1995-01-25 | 1997-05-27 | Ransburg Corporation | Rotary powder applicator |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
JP3770333B2 (ja) | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | 組換えdnaウイルスおよびその製造方法 |
WO1996037621A2 (en) * | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Multimeric proteins |
US6110456A (en) | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
JP2783276B2 (ja) * | 1995-07-04 | 1998-08-06 | 日本電気株式会社 | 半導体装置の製造方法 |
EP0932671A2 (de) | 1995-07-31 | 1999-08-04 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Verlängerung einer oberfläche, die eine protein-protein-wechselwirkung bewirkt, um die funktion eines zellulären proteins zu inaktivieren |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
CA2239303A1 (en) | 1995-12-22 | 1997-07-03 | Somatogen, Inc. | Globins containing binding domains |
ES2260788T3 (es) * | 1996-03-25 | 2006-11-01 | Medarex, Inc. | Anticuerpos monoclonales especificos para el dominio estracelular de antigeno de membrana especifico de la prostata. |
US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
US6096291A (en) | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
EP0971959B1 (de) * | 1997-04-07 | 2005-12-28 | Genentech, Inc. | Humanisierte antikörper und verfahren zu ihrer herstellung |
ATE293994T1 (de) | 1997-12-01 | 2005-05-15 | Fang Fang | Multivalente rekombinante antikörper zur behandlung von hrv infektionen |
JPH11228446A (ja) * | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | 抗マラリア剤 |
US20020165153A1 (en) | 1998-04-06 | 2002-11-07 | Peter Angel | Transcription factors and their use |
US5965712A (en) * | 1998-06-19 | 1999-10-12 | Virginia Commonwealth University | LZ-CD23 chimera for inhibition of IgE-mediated allergic disease |
CN100480266C (zh) * | 1998-10-16 | 2009-04-22 | 拜奥根Idec马萨诸塞公司 | 干扰素-β融合蛋白及用途 |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
JP2002531466A (ja) * | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス, インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
EP1194539A2 (de) | 1999-06-25 | 2002-04-10 | Universität Zürich | Hetero-assoziierende coiled-coil peptide und screenings-verfahren dafür |
HUP0202702A2 (hu) | 1999-09-17 | 2002-12-28 | Genzyme Transgenics Corporation | Alegységoptimalizált fúziós fehérjék és alkalmazásai |
AUPQ425699A0 (en) * | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
JP2003516150A (ja) * | 1999-12-08 | 2003-05-13 | ジェンセット | 潜在性分泌タンパク質をコードする全長ヒトcDNA |
JP5008811B2 (ja) | 2000-04-28 | 2012-08-22 | プラネット・バイオテクノロジー・インコーポレイテッド | ライノウイルス感染を防止するための免疫接着物 |
EP1578917A4 (de) * | 2001-07-19 | 2008-01-23 | Perlan Therapeutics Inc | Multimere proteine und verfahren zu deren herstellung und verwendung |
JP4236000B2 (ja) | 2003-09-25 | 2009-03-11 | 元気株式会社 | 3次元画像処理装置、3次元画像処理方法及びプログラム |
-
2001
- 2001-07-19 US US09/910,483 patent/US20030035798A1/en not_active Abandoned
-
2002
- 2002-07-19 CA CA2454361A patent/CA2454361C/en not_active Expired - Fee Related
- 2002-07-19 DE DE60238485T patent/DE60238485D1/de not_active Expired - Lifetime
- 2002-07-19 EP EP02798403A patent/EP1414861B1/de not_active Expired - Lifetime
- 2002-07-19 CA CA2793019A patent/CA2793019A1/en not_active Abandoned
- 2002-07-19 WO PCT/US2002/023002 patent/WO2003035696A2/en active Application Filing
- 2002-07-19 DK DK02798403.8T patent/DK1414861T3/da active
- 2002-07-19 ES ES02798403T patent/ES2356896T3/es not_active Expired - Lifetime
- 2002-07-19 AU AU2002363027A patent/AU2002363027C1/en not_active Ceased
- 2002-07-19 EP EP10010857A patent/EP2336186A1/de not_active Withdrawn
- 2002-07-19 AT AT02798403T patent/ATE490276T1/de not_active IP Right Cessation
- 2002-07-19 JP JP2003538209A patent/JP4516312B2/ja not_active Expired - Fee Related
-
2006
- 2006-09-11 US US11/519,322 patent/US7696324B2/en not_active Expired - Fee Related
-
2008
- 2008-12-18 AU AU2008258214A patent/AU2008258214B2/en not_active Ceased
-
2009
- 2009-05-15 JP JP2009119326A patent/JP2009183303A/ja active Pending
-
2010
- 2010-03-26 US US12/748,304 patent/US8586712B2/en not_active Expired - Fee Related
-
2012
- 2012-06-07 AU AU2012203365A patent/AU2012203365A1/en not_active Abandoned
-
2013
- 2013-02-14 JP JP2013026399A patent/JP2013116119A/ja active Pending
- 2013-11-18 US US14/083,146 patent/US20140308269A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE490276T1 (de) | 2010-12-15 |
EP2336186A1 (de) | 2011-06-22 |
US8586712B2 (en) | 2013-11-19 |
DK1414861T3 (da) | 2011-03-21 |
US20110044976A1 (en) | 2011-02-24 |
WO2003035696A3 (en) | 2003-11-27 |
JP4516312B2 (ja) | 2010-08-04 |
CA2793019A1 (en) | 2003-05-01 |
CA2454361A1 (en) | 2003-05-01 |
ES2356896T3 (es) | 2011-04-14 |
JP2005524385A (ja) | 2005-08-18 |
EP1414861B1 (de) | 2010-12-01 |
US20070071742A1 (en) | 2007-03-29 |
US20030035798A1 (en) | 2003-02-20 |
AU2008258214B2 (en) | 2012-03-08 |
CA2454361C (en) | 2013-01-08 |
JP2009183303A (ja) | 2009-08-20 |
AU2002363027C1 (en) | 2009-04-30 |
US20140308269A1 (en) | 2014-10-16 |
JP2013116119A (ja) | 2013-06-13 |
US7696324B2 (en) | 2010-04-13 |
WO2003035696A2 (en) | 2003-05-01 |
AU2002363027B2 (en) | 2008-09-18 |
EP1414861A2 (de) | 2004-05-06 |
AU2008258214A1 (en) | 2009-01-15 |
AU2012203365A1 (en) | 2012-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60238485D1 (de) | Humanisierte antikörper gegen icam-1, deren herstellung und verwendungen | |
DE60140973D1 (de) | Kristallines und reines Modafinil und Verfahren zu seiner Herstellung | |
DE50303413D1 (de) | Befestigungsmittel und Verfahren zu seiner Herstellung | |
MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
DE122012000001I1 (de) | Humane antikorper gegen CTLA-4 und deren verwendungen. | |
CY1109151T1 (el) | Αντισωματα dr4 και χρησεις αυτων | |
ATE333895T1 (de) | Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4 | |
ATE309196T1 (de) | Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte | |
DE60013228D1 (de) | Sorptionsfähige verbundwerkstoffe die unabhängig sind von aktivierungsbehandlungen und verfahren zur herstellung | |
DE60141855D1 (de) | Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i | |
DE59914538D1 (de) | Tetravalente Antikörperkonstrukte | |
CY1110537T1 (el) | Ενωσεις και μεθοδοι για την αγωγη της δυσλιπιδαιμιας | |
ATE366746T1 (de) | Gegen das semp1-protein gerichtete antikörper, verfahren zu deren herstellung, und deren anwendungen | |
DE60328502D1 (de) | Verfahren zur herstellung von 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazolen aus cyclohexanen und cycylohexanonen als zwischenprodukte | |
DE60214035D1 (de) | Olefinisches thermoplastisches elastomer, verfahren zu seiner herstellung, olefinisches thermoplastisches elastomer enthaltende zusammensetzungen, verfahren zu ihrer herstellung und formkörper daraus | |
DE60017341D1 (de) | Emulsion, und Verfahren zur Herstellung von Emulsionen und öligen Zusammensetzungen | |
DE60227517D1 (de) | Verfahren zur herstellung von 10,11 dihydro 10 hydroxy 5h-dibenz/b,f/azepin-5-carbonsäureamid und 10,11 dihydro 10 oxo-5h-dibenz/b,f/azepin-5 carbonsäureamid | |
ATE362490T1 (de) | Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung | |
DE69426767D1 (de) | Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen. | |
DE69205752T2 (de) | Katalytische Zusammensetzung zum Deodorieren von Gasen und Verfahren zur Herstellung derselben. | |
DE69809284D1 (de) | Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen | |
DE60224884D1 (de) | Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen | |
DE69401424T2 (de) | Verfahren zur herstellung von musikinstrumenten und nach diesem verfahren hergestellte musikinstrumente | |
DE60222806D1 (de) | Verfahren zur herstellung von (1,4,5)-oxadiazepinderivaten | |
ATE353886T1 (de) | Verbindungen und verfahren zur behandlung einer hyperaktiven blase |